Research
Hormonal
The blood pressure-lowering effects of GLP-1 RAs are often independent of weight loss or glucose control.
GLP-1 RAs may be beneficial for hypertension management even in patients not focused on weight loss or glucose control.
StrongSupportsmedium confidence
The blood pressure-lowering effects, often independent of weight loss or glucose control, warrant further investigation.
Why this rating
Based on the implications discussed in the abstract.
Source
Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Diana De Oliveira-Gomes et al. · Current Opinion in Cardiology · 2025
DOI 10.1097/hco.0000000000001225
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →